secwatch.observer — SEC 8-K summary
======================================

Issuer:     JOHNSON & JOHNSON (JNJ)
CIK:        0000200406
Form:       8-K
Filed at:   2024-04-16T23:59:59+00:00
Accession:  0000200406-24-000031
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

JNJ reports Q1 adjusted EPS $2.71 (+12.4% YoY); declares 4.2% dividend increase to $1.24/quarter
--------------------------------------------------------------------------------

- Worldwide sales $21.38B, up 2.3% total (6.0% ex-COVID-19 vaccine); MedTech up 4.5%, Innovative Medicine ex-vaccine up 6.9%
- GAAP net earnings from continuing ops $5.35B ($2.20 diluted EPS) vs $0.49B loss in prior year (large litigation charges skewed comparison)
- Adjusted net earnings $6.58B, up 3.8%; adjusted diluted EPS $2.71 vs $2.41, +12.4%
- Board raises quarterly dividend to $1.24/share (from $1.19), a 4.2% increase; marks 62nd consecutive annual increase
- New indicated annual dividend $4.96/share; payable June 4, 2024 to holders of record May 21, 2024

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/200406/000020040624000031/0000200406-24-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/200406/000020040624000031/jnj-20240416.htm
  HTML page:      https://secwatch.observer/filing/0000200406-24-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer